US FDA grants Orphan Drug Designation to umbralisib for the treatment of follicular lymphoma (FL)

Umbralisib is a dual inhibitor of PI3K-delta and CK1-epsilon. The UNITY-NHL Phase 2b trial is investigating its use in various types of lymphoma; the FL cohort includes patients who have received at least two prior lines of therapy including an anti-CD20 monoclonal antibody.


Biospace Inc.